{"drugs":["Corifact","Factor XIII Human"],"mono":{"0":{"id":"929808-s-0","title":"Generic Names","mono":"Factor XIII Human"},"1":{"id":"929808-s-1","title":"Dosing and Indications","sub":[{"id":"929808-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bleeding - Hereditary factor XIII deficiency disease - Surgical procedure:<\/b> individualize dose based on patient's factor XIII activity, type of surgery, and clinical response; last prophylactic dose within 7 days, no dose may be needed; last prophylactic dose 8 to 21 days prior, partial or full dose (based on patient's last prophylactic dose) may be necessary depending on factor XIII activity level; last prophylactic dose 21 to 28 days prior, administer full prophylactic dose<\/li><li><b>Hereditary factor XIII deficiency disease; Prophylaxis:<\/b> initial, 40 international units\/kg IV; dose every 28 days to maintain trough Factor XIII activity level between 5% and 20%; adjust based on trough Factor XIII activity levels and patient's clinical condition<\/li><\/ul>"},{"id":"929808-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>less than 16 years of age:<\/b> may require dose adjustment due to shorter half-life and faster clearance than adults<\/li><li><b>Bleeding - Hereditary factor XIII deficiency disease - Surgical procedure:<\/b> individualize dose based on patient's factor XIII activity, type of surgery, and clinical response<\/li><li><b>Bleeding - Hereditary factor XIII deficiency disease - Surgical procedure:<\/b> last prophylactic dose within 7 days, no dose may be needed<\/li><li><b>Bleeding - Hereditary factor XIII deficiency disease - Surgical procedure:<\/b> last prophylactic dose 8 to 21 days prior, partial or full dose (based on patient's last prophylactic dose) may be necessary depending on factor XIII activity level<\/li><li><b>Bleeding - Hereditary factor XIII deficiency disease - Surgical procedure:<\/b> last prophylactic dose 21 to 28 days prior, administer full prophylactic dose<\/li><li><b>Hereditary factor XIII deficiency disease; Prophylaxis:<\/b> initial, 40 international units\/kg IV; dose every 28 days to maintain trough Factor XIII activity level between 5% and 20%; adjust based on trough Factor XIII activity levels and patient's clinical condition<\/li><\/ul>"},{"id":"929808-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Berichrom Activity Assay, one trough Factor XIII activity level less than 5%:<\/b> increase dose by 5 international units\/kg<\/li><li><b>Berichrom Activity Assay, trough Factor XIII activity level between 5% to 20%:<\/b> no dosage change<\/li><li><b>Berichrom Activity Assay, two trough Factor XIII activity levels of greater than 20%:<\/b> decrease dose by 5 international units\/kg<\/li><li><b>Berichrom Activity Assay, one trough Factor XIII activity level of greater than 25%:<\/b> decrease dose by 5 international units\/kg<\/li><\/ul>"},{"id":"929808-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding - Hereditary factor XIII deficiency disease - Surgical procedure<\/li><li>Hereditary factor XIII deficiency disease; Prophylaxis<\/li><\/ul>"}]},"3":{"id":"929808-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929808-s-3-9","title":"Contraindications","mono":"anaphylactic or severe systemic reaction to human plasma-derived products or to any other component of the product <br\/>"},{"id":"929808-s-3-10","title":"Precautions","mono":"<ul><li>human plasma derivative; infectious agent risk including viruses and theoretical risk of Creutzfeldt-Jakob disease agent<\/li><li>hypersensitivity reactions have been reported; if anaphylaxis or hypersensitivity reaction occur, immediately discontinue<\/li><li>inhibitory antibodies have been detected; monitoring recommended<\/li><li>thromboembolic complications have been reported; monitoring recommended for patient with known risk factors<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929808-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929808-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929808-s-4","title":"Drug Interactions","sub":{"1":{"id":"929808-s-4-14","title":"Major","mono":"<ul>Coagulation Factor VIIa (theoretical)<\/ul>"}}},"5":{"id":"929808-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema (greater than 1%), Pruritus of skin (greater than 1%), Rash (greater than 1%)<\/li><li><b>Endocrine metabolic:<\/b>Serum lactate dehydrogenase level elevated (greater than 1%)<\/li><li><b>Hematologic:<\/b>Blood coagulation disorder (greater than 1%), Hematoma (greater than 1%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (greater than 1%), Arthritis (greater than 1%)<\/li><li><b>Neurologic:<\/b>Headache (greater than 1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Ischemia (0.5%)<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Antibody development, Hypersensitivity reaction (greater than 1%)<\/li><\/ul>"},"6":{"id":"929808-s-6","title":"Drug Name Info","sub":{"0":{"id":"929808-s-6-17","title":"US Trade Names","mono":"Corifact<br\/>"},"2":{"id":"929808-s-6-19","title":"Class","mono":"Hemostatic<br\/>"},"3":{"id":"929808-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929808-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929808-s-7","title":"Mechanism Of Action","mono":"Factor XIII is a naturally occurring glycoprotein in plasma that promotes cross-linking of fibrin during the coagulation process, and protects the newly formed clot from fibrinolysis. Factor XIII is a proenzyme which is activated in the presence of calcium ion, to form activated factor XIIIa. The activated form is homodimeric, with only the A-subunit having intracellular activity. The B-subunit has no enzymatic activity and functions to stabilize the structure against proteolysis.<br\/>"},"8":{"id":"929808-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929808-s-8-23","title":"Absorption","mono":"Tmax, IV: 1.7 hr <br\/>"},"1":{"id":"929808-s-8-24","title":"Distribution","mono":"Vd, 51.1 mL\/kg <br\/>"},"3":{"id":"929808-s-8-26","title":"Excretion","mono":"clearance: adults 0.22 mL\/hr\/kg; children 0.29 mL\/hr\/kg <br\/>"},"4":{"id":"929808-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adults, 7.1 days<\/li><li>Children, 5.7 days<\/li><\/ul>"}}},"9":{"id":"929808-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with 20 mL sterile water for injection<\/li><li>use within 4 hours after reconstitution; do not refrigerate or freeze reconstituted solution<\/li><li>reconstituted solution should be at room temperature upon administration<\/li><li>administer at a rate not exceeding 4 mL\/min<\/li><\/ul>"},"10":{"id":"929808-s-10","title":"Monitoring","mono":"<ul><li>trough factor XIII activity levels during treatment, and during and after surgery, to maintain an activity level of 5% to 20%<\/li><li>inhibitory antibody formation<\/li><li>thromboembolic complications; patients with known risk factors<\/li><\/ul>"},"11":{"id":"929808-s-11","title":"How Supplied","mono":"<b>Corifact<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/>"},"13":{"id":"929808-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug is made from human plasma. Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional, and patients receiving repeated\/regular therapy should consider appropriate vaccinations when possible (ie, Hepatitis A and B).<\/li><li>This drug may cause thrombosis or embolism.<\/li><li>This drug may cause flu-like symptoms, arthralgia, and pyrexia.<\/li><li>Drug may cause abdominal pain, diarrhea, or vomiting.<\/li><li>Instruct patients to report spontaneous bleeding episodes while receiving treatment with coagulation factor XIII, as this may indicate the development of inhibitory antibodies against factor XIII which render the medication less effective.<\/li><\/ul>"}}}